Genital Diseases, Female  >>  everolimus  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
everolimus / Generic mfg.
ENDORAD, NCT00870337 / 2007-003002-10: Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer

Checkmark
Apr 2013 - Apr 2013: 
Checkmark P2 data: (SABCS 2012)
Dec 2012 - Dec 2012: P2 data: (SABCS 2012)
Checkmark P2 data
More
Completed
2
44
Europe
everolimus
ARCAGY/ GINECO GROUP
Endometrial Cancer
05/11
 
NCT01031381: Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Completed
2
50
US
RAD001, everolimus, derivative of rapamycin, bevacizumab, Avastin
University of Pittsburgh, Novartis Pharmaceuticals, Genentech, Inc.
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
01/14
12/14
NCT00087685: RAD001 in Recurrent Endometrial Cancer Patients

Completed
2
35
US
RAD001
M.D. Anderson Cancer Center
Endometrial Cancer
01/15
01/15
NCT01149434: Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers

Terminated
1/2
19
US
JI-101, Everolimus, RAD001
University of Utah, Jubilant Innovation Ltd.
Cancer, Neuroendocrine, Ovarian Cancer, Colon Cancer
08/12
08/12

Download Options